Does the media prefer VVOS or PSTV?

In the previous week, Plus Therapeutics had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Vivos Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Vivos Therapeutics' score of 0.94 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PETV or VVOS?

Vivos Therapeutics has a consensus price target of $2.80, indicating a potential upside of 525.56%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is PETV or VVOS more profitable?

Vivos Therapeutics has a net margin of -127.70% compared to PetVivo's net margin of -902.82%. Vivos Therapeutics' return on equity of -2,325.64% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% Vivos Therapeutics -127.70% -2,325.64% -98.12%

Does the media refer more to PETV or VVOS?

In the previous week, PetVivo and PetVivo both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 0.94 beat PetVivo's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLSS or VVOS?

In the previous week, Vivos Therapeutics had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Milestone Scientific. Vivos Therapeutics' average media sentiment score of 0.94 beat Milestone Scientific's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NMTC or VVOS?

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for NeuroOne Medical Technologies and 2 mentions for Vivos Therapeutics. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Vivos Therapeutics' score of 0.94 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vivos Therapeutics (VVOS) Competitors

$0.45 +0.01 (+3.13%)

Closing price 04:00 PM Eastern

Extended Trading

$0.45 0.00 (-0.13%)

As of 07:26 PM Eastern

Compare

VVOS vs. PSTV, PETV, MLSS, NMTC, and CTSO

Should you buy Vivos Therapeutics stock or one of its competitors? MarketBeat compares Vivos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vivos Therapeutics include Plus Therapeutics (PSTV), PetVivo (PETV), Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.

How does Vivos Therapeutics compare to Plus Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 525.56%. Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,242.86%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Vivos Therapeutics has a net margin of -127.70% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Vivos Therapeutics has a beta of 6.1, suggesting that its share price is 510% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Vivos Therapeutics has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A
Plus Therapeutics	$5.21M	5.55	-$22.39M	-$2.30	N/A

In the previous week, Plus Therapeutics had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Vivos Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Vivos Therapeutics' score of 0.94 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Plus Therapeutics beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to PetVivo?

PetVivo (NASDAQ:PETV) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

PetVivo has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, suggesting that its stock price is 510% more volatile than the broader market.

24.5% of PetVivo shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 10.8% of PetVivo shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vivos Therapeutics has a net margin of -127.70% compared to PetVivo's net margin of -902.82%. Vivos Therapeutics' return on equity of -2,325.64% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

PetVivo has higher earnings, but lower revenue than Vivos Therapeutics. PetVivo is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	29.60	-$10.95M	-$0.38	N/A
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A

In the previous week, PetVivo and PetVivo both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 0.94 beat PetVivo's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivos Therapeutics has a consensus price target of $2.80, indicating a potential upside of 525.56%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Vivos Therapeutics beats PetVivo on 11 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 12.5% of Milestone Scientific shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Milestone Scientific currently has a consensus price target of $1.00, suggesting a potential upside of 212.79%. Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 525.56%. Given Vivos Therapeutics' higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Milestone Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Milestone Scientific has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, meaning that its share price is 510% more volatile than the broader market.

Milestone Scientific has a net margin of -52.01% compared to Vivos Therapeutics' net margin of -127.70%. Milestone Scientific's return on equity of -60.26% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

In the previous week, Vivos Therapeutics had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Milestone Scientific. Vivos Therapeutics' average media sentiment score of 0.94 beat Milestone Scientific's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Scientific	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Scientific has higher earnings, but lower revenue than Vivos Therapeutics. Milestone Scientific is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	3.18	-$6.93M	-$0.05	N/A
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A

Summary

Milestone Scientific and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NeuroOne Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, meaning that its stock price is 510% more volatile than the broader market.

NeuroOne Medical Technologies has higher earnings, but lower revenue than Vivos Therapeutics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	2.40	-$3.61M	-$0.85	N/A
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A

NeuroOne Medical Technologies has a net margin of -68.35% compared to Vivos Therapeutics' net margin of -127.70%. NeuroOne Medical Technologies' return on equity of -99.43% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for NeuroOne Medical Technologies and 2 mentions for Vivos Therapeutics. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Vivos Therapeutics' score of 0.94 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroOne Medical Technologies presently has a consensus target price of $11.67, suggesting a potential upside of 249.30%. Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 525.56%. Given Vivos Therapeutics' higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

NeuroOne Medical Technologies beats Vivos Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 7.3% of Cytosorbents shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Vivos Therapeutics had 1 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Vivos Therapeutics' score of 0.94 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
Vivos Therapeutics	Positive

Cytosorbents has higher revenue and earnings than Vivos Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A

Cytosorbents presently has a consensus price target of $5.38, suggesting a potential upside of 1,384.81%. Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 525.56%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cytosorbents has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, indicating that its share price is 510% more volatile than the broader market.

Cytosorbents has a net margin of -31.85% compared to Vivos Therapeutics' net margin of -127.70%. Cytosorbents' return on equity of -235.57% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Summary

Cytosorbents beats Vivos Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.03M	$3.02B	$6.71B	$12.23B
Dividend Yield	N/A	1.77%	2.67%	6.10%
P/E Ratio	-0.21	19.27	26.03	24.18
Price / Sales	0.32	323.43	556.43	100.98
Price / Cash	N/A	56.66	46.99	54.37
Price / Book	-2.80	4.21	10.77	6.35
Net Income	-$21.17M	$64.45M	$3.57B	$337.63M
7 Day Performance	-10.48%	2.24%	3.15%	-0.30%
1 Month Performance	-30.79%	1.74%	2.33%	0.36%
1 Year Performance	-86.72%	26.63%	33.42%	26.94%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	3.4246 of 5 stars	$0.45 +3.1%	$2.80 +525.6%	-85.8%	$6.03M	$19.57M	N/A	160
PSTV Plus Therapeutics	2.4607 of 5 stars	$4.57 -5.8%	$56.40 +1,134.1%	-45.9%	$31.46M	N/A	N/A	20	News Coverage
PETV PetVivo	N/A	$0.85 +6.3%	N/A	+1.3%	$30.96M	$1.05M	N/A	20	News Coverage Upcoming Earnings High Trading Volume
MLSS Milestone Scientific	1.248 of 5 stars	$0.34 +0.6%	$1.00 +194.1%	-57.0%	$30.07M	$8.90M	N/A	30	News Coverage
NMTC NeuroOne Medical Technologies	2.8055 of 5 stars	$3.25 -2.1%	$11.67 +259.0%	-26.5%	$28.62M	$9.72M	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. PSTV, PETV, MLSS, NMTC, and CTSO

How does Vivos Therapeutics compare to Plus Therapeutics?

Summary

How does Vivos Therapeutics compare to PetVivo?

Summary

How does Vivos Therapeutics compare to Milestone Scientific?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Summary

How does Vivos Therapeutics compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. PSTV, PETV, MLSS, NMTC, and CTSO

How does Vivos Therapeutics compare to Plus Therapeutics?

Do analysts prefer VVOS or PSTV?

Is VVOS or PSTV more profitable?

Which has more volatility and risk, VVOS or PSTV?

Which has better valuation & earnings, VVOS or PSTV?

Does the media prefer VVOS or PSTV?

Do insiders and institutionals believe in VVOS or PSTV?

Summary

How does Vivos Therapeutics compare to PetVivo?

Which has more volatility and risk, PETV or VVOS?

Do institutionals and insiders have more ownership in PETV or VVOS?

Is PETV or VVOS more profitable?

Which has stronger earnings and valuation, PETV or VVOS?

Does the media refer more to PETV or VVOS?

Do analysts recommend PETV or VVOS?

Summary

How does Vivos Therapeutics compare to Milestone Scientific?

Do insiders & institutionals hold more shares of MLSS or VVOS?

Do analysts rate MLSS or VVOS?

Which has more volatility and risk, MLSS or VVOS?

Is MLSS or VVOS more profitable?

Does the media favor MLSS or VVOS?

Which has better valuation and earnings, MLSS or VVOS?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Do insiders and institutionals hold more shares of NMTC or VVOS?

Which has more volatility & risk, NMTC or VVOS?

Which has higher earnings & valuation, NMTC or VVOS?

Is NMTC or VVOS more profitable?

Does the media favor NMTC or VVOS?

Do analysts rate NMTC or VVOS?

Summary

How does Vivos Therapeutics compare to Cytosorbents?

Do institutionals & insiders hold more shares of CTSO or VVOS?

Does the media favor CTSO or VVOS?

Which has preferable valuation and earnings, CTSO or VVOS?

Do analysts recommend CTSO or VVOS?

Which has more risk & volatility, CTSO or VVOS?

Is CTSO or VVOS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools